Hence, PI3K/Akt inhibition blocks insulin-driven glucose uptake, resulting in a dose-dependent increase in plasma levels of fasting C-peptide and insulin, thus causing hyperglycemia (62). This evidence concerns the gene AKT1 and Hyperglycemia.